SEROMETRIX is redefining drug discovery.

A biotechnology drug discovery and development company, Serometrix is delivering better answers by asking better questions. Seeking a way to overcome the shortcomings of 'one drug - one target' approaches, the company developed SimPep™, the company's in silico discovery platform, to probe nature in novel ways to:

• Identify relevant targets critical to positively impacting a particular disease
• "Mine" highly evolved peptide sequences that the human system utilizes against these targets to positively impact the disease

Utilizing this platform, Serometrix harnesses the clinically predictive power inherent within the human system; the only rational approach that promises to immediately and dramatically enhance productivity in drug development. SimPep™ rapidly screens these human proteins, generating short peptide compounds that can treat disease with high efficacy and predictable side effects.